Patent approval for Therapeutic use of Arsenic and Metal Ions

A key new patent covering the ‘Use of metal ions to potentiate the therapeutic effects of arsenic’ has been issued to clinical-stage company BioSenic by the China National Intellectual Property Administration (CNIPA). The patent (ZL202080040613.1) covers the use of its ATO platform in combination with metal ions like copper, which has the potential to improve the treatment of autoimmune diseases. The European Patent Office (EPO) granted similar protection (EP3972613) in April 2023.

These intellectual property rights pave the way for clinical and commercial developments by the company and interested partners in two main immediate areas of application; immune and autoimmune related diseases such as chronic Graft-versus-Host Diseases (cGvHD), systemic sclerosis and systemic lupus erythematosus, and also in oncology, where ATO has already demonstrated exceptional results for patients, including complete remission of acute promyelocytic leukaemia.

“BioSenic's new patent in China opens up new avenues of industrial development for the treatment of diseases with clinical unmet medical needs in the fields of cancer, autoimmunity and infectious diseases, in Asia and elsewhere,” said François Rieger, PhD, Chairman and Chief Executive Officer of BioSenic. “We are thrilled to open up new chapters in the continuous worldwide effort in trying to control lethal diseases with no real cure.”

More information online